

IQWiG Reports - Commission No. A21-19

Durvalumab (small cell lung cancer) –

2nd Addendum to Commission A20-87¹

Addendum

Commission: A21-19Version:1.0Status:12 March 2021

¹ Translation of addendum A21-19 *Durvalumab (kleinzelliges Lungenkarzinom)* – 2. Addendum zum Auftrag A20-87 (Version 1.0; Status: 12. March 2021). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.

Publishing details

Publisher

Institute for Quality and Efficiency in Health Care

Topic

Durvalumab (small cell lung cancer) - 2nd Addendum to Commission A20-87

Commissioning agency Federal Joint Committee

Commission awarded on 9 February 2021

Internal Commission No. A21-19

Address of publisher

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany

Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: <u>berichte@iqwig.de</u> Internet: <u>www.iqwig.de</u>

IQWiG employees involved in the addendum

- Philip Kranz
- Lars Beckmann
- Daniela Preukschat
- Volker Vervölgyi

Keywords: Durvalumab, Etoposide, Carboplatin, Cisplatin, Small Cell Lung Carcinoma, Benefit Assessment, NCT03043872

Table of contents

Page

Lis	t o	f tabl	les	iv
Lis	st o	f figu	ires	v
Lis	st o	f abb	reviationsv	'ii
1	B	ackgı	round	1
2	A	ssessi	ment	2
2	2.1	Mo	orbidity (symptoms and health status) and health-related quality of life	2
	2	.1.1	Event time analyses on the instruments EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS	.2
	2	.1.2	MMRM analyses on the instruments EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS	.2
	2	.1.3	Event time analyses on the PGIC instrument	3
2	2.2	Sid	le effects	3
	2	.2.1	Analyses on AEs irrespective of the start of a subsequent therapy	3
	2	.2.2	Immune-related severe AEs (CTCAE grade \geq 3) in women	4
2	2.3	Su	mmary	4
3	R	efere	nces	6
Ар			A – Event time analyses PGIC, EQ-5D VAS, EORTC QLQ-C30 + LC13, AEs irrespective of the start of subsequent therapy	.7
A	\.1	– Ev	ent time analyses PGIC and EQ-5D VAS	7
A	٩.2	– Ka	plan-Meier curves EQ-5D VAS	8
A	٩.3	– Ev	ent time analyses EORTC QLQ-C30 and QLQ-LC13	9
A	\.4	– Ka	plan-Meier curves on EORTC QLQ-C30 and QLQ-LC13 symptom scales 1	4
P	4.5		plan-Meier curves on global health status and EORTC QLQ-C30 actional scales	23
A	4.6	– AF	Es irrespective of the start of a subsequent therapy	26

List of tables

Pa	age
Table 1: Durvalumab + chemotherapy – probability and extent of added benefit	5
Table 2: Results (morbidity, time to event) – RCT, direct comparison: durvalumab + chemotherapy vs. chemotherapy	7
Table 3: Results (morbidity, health-related quality of life) – RCT, direct comparison: durvalumab + chemotherapy vs. chemotherapy	9
Table 4: Results (side effects) – RCT, direct comparison: durvalumab + chemotherapy vs. chemotherapy	26

Durvalumab – Addendum to Commission A20-87

List of figures

Pa	age
Figure 1: Kaplan-Meier curves on health status, EQ-5D VAS	8
Figure 2: Kaplan-Meier curves on symptoms, symptom scale "fatigue" (EORTC QLQ- C30)	14
Figure 3: Kaplan-Meier curves on symptoms, symptom scale "nausea and vomiting" (EORTC QLQ-C30)	14
Figure 4: Kaplan-Meier curves on symptoms, symptom scale "pain" (EORTC QLQ-C30)	15
Figure 5: Kaplan-Meier curves on symptoms, symptom scale "dyspnoea" (EORTC QLQ-C30)	15
Figure 6: Kaplan-Meier curves on symptoms, symptom scale "insomnia" (EORTC QLQ- C30)	16
Figure 7: Kaplan-Meier curves on symptoms, symptom scale "appetite loss" (EORTC QLQ-C30)	16
Figure 8: Kaplan-Meier curves on symptoms, symptom scale "constipation" (EORTC QLQ-C30)	17
Figure 9: Kaplan-Meier curves on symptoms, symptom scale "diarrhoea" (EORTC QLQ-C30)	
Figure 10: Kaplan-Meier curves on symptoms, symptom scale "alopecia" (EORTC QLQ-LC13)	
Figure 11: Kaplan-Meier curves on symptoms, symptom scale "haemoptysis" (EORTC QLQ-LC13)	18
Figure 12: Kaplan-Meier curves on symptoms, symptom scale "dysphagia" (EORTC QLQ-LC13)	19
Figure 13: Kaplan-Meier curves on symptoms, symptom scale "dyspnoea" (EORTC QLQ-LC13)	19
Figure 14: Kaplan-Meier curves on symptoms, symptom scale "cough" (EORTC QLQ- LC13)	20
Figure 15: Kaplan-Meier curves on symptoms, symptom scale "sore mouth" (EORTC QLQ-LC13)	20
Figure 16: Kaplan-Meier curves on symptoms, symptom scale "peripheral neuropathy" (EORTC QLQ-LC13)	21
Figure 17: Kaplan-Meier curves on symptoms, symptom scale "pain (arm/shoulder)" (EORTC QLQ-LC13)	21
Figure 18: Kaplan-Meier curves on symptoms, symptom scale "pain (chest)" (EORTC QLQ-LC13)	
Figure 19: Kaplan-Meier curves on symptoms, symptom scale "pain (other)" (EORTC QLQ-LC13)	22
Figure 20: Kaplan-Meier curves on health-related quality of life, scale "global health status" (EORTC QLQ-C30)	23

Addendum A21-19	Version 1.0
Durvalumab – Addendum to Commission A20-87	12 March 2021
Figure 21: Kaplan-Meier curves on health-related quality of life, scale "physi functioning" (EORTC QLQ-C30)	
Figure 22: Kaplan-Meier curves on health-related quality of life, scale "role f (EORTC QLQ-C30)	•
Figure 23: Kaplan-Meier curves on health-related quality of life, scale "emoti functioning" (EORTC QLQ-C30)	
Figure 24: Kaplan-Meier curves on health-related quality of life, scale "cogni functioning" (EORTC QLQ-C30)	
Figure 25: Kaplan-Meier curves on health-related quality of life, scale "social functioning" (EORTC QLQ-C30)	

Abbreviation	Meaning
AE	adverse event
CTCAE	Common Terminology Criteria for Adverse Events
EORTC	European Organisation for Research and Treatment of Cancer
ES-SCLC	extensive-stage small cell lung cancer
EQ-5D	European Quality of Life-5 Dimensions
G-BA	Gemeinsamer Bundesausschuss (Federal Joint Committee)
IQWiG	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care)
MMRM	mixed-effects model with repeated measures
PGIC	Patient Global Impression of Change
РТ	Preferred Term
QLQ-C30	Quality of Life Questionnaire-Core 30
QLQ-LC13	Quality of Life Questionnaire-Lung Cancer 13
SAE	serious adverse event
SOC	System Organ Class
VAS	visual analogue scale

List of abbreviations

1 Background

On 9 February 2021, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct supplementary assessments for Commission A20-87 (Durvalumab – Benefit assessment according to §35a Social Code Book V) [1].

In its dossier [2], the pharmaceutical company (hereinafter referred to as "the company") presented results of the CASPIAN study on the comparison of durvalumab in combination with etoposide and either carboplatin or cisplatin (hereinafter referred to as "durvalumab + chemotherapy") versus etoposide with either carboplatin or cisplatin (hereinafter referred to as "durvalumab + chemotherapy") in patients with extensive-stage small cell lung cancer (ES-SCLC). The CASPIAN study recorded patient-reported outcomes using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-C30 and QLQ-LC13), the European Quality of Life-5 Dimensions visual analogue scale (EQ-5D VAS), and the Patient Global Impression of Change (PGIC). For the benefit assessment, mixed-effects model with repeated measures (MMRM) analyses were used for the EORTC QLQ-C30 and QLQ-LC13 as well as the EQ-5D VAS, as not all recorded data were included in the event time analyses presented by the company in the dossier. The company's dossier contained no usable data for the PGIC.

With its comments [3,4], the company, on the one hand, subsequently submitted information on the heterogeneity of the results between the cohorts (heterogeneity tests) and subgroup analyses for the MMRM analyses (EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS). On the other hand, the company subsequently submitted event time analyses over the entire documentation period for these outcomes after the oral hearing [5]. In addition, the company's comments included event time analyses for the PGIC instrument and data on adverse events (AEs) with a follow-up observation period of 90 days, irrespective of the start of subsequent therapy.

The G-BA commissioned IQWiG with the assessment of the following additional data submitted by the company under consideration of the information provided in the dossier:

- analyses of heterogeneity tests for the factor cohort and subgroup analyses for the MMRM analyses or, if subsequently submitted by the company after the oral hearing, analysis of the event time analyses for the patient-reported outcomes recorded using the instruments EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS
- event time analyses (time to deterioration) of the PGIC
- AEs up to 90 days after discontinuation of the study medication (irrespective of the start of subsequent therapy)

The responsibility for the present assessment and the assessment result lies exclusively with IQWiG. The assessment is forwarded to the G-BA. The G-BA decides on the added benefit.

2 Assessment

2.1 Morbidity (symptoms and health status) and health-related quality of life

2.1.1 Event time analyses on the instruments EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS

The event time analyses for the patient-reported outcomes recorded using EORTC QLQ-C30, QLQ-LC13 (time to first deterioration by 10 points) and EQ-5D VAS (time to deterioration by 7 or 10 points) presented in the company's dossier are not suitable for the benefit assessment, as only events up to cycle 6 were included in the analyses [1,2]. After the oral hearing, the company submitted event time analyses for the mentioned outcomes over the entire documentation period based on the meta-analysis (global cohort and cohort in China) [5]. These analyses were incomplete, however. Subgroup analyses as well as heterogeneity tests for the factor cohort and analyses for the individual cohorts were missing.

There was a relevant difference in event rates between the results of the subsequently submitted event time analyses over the entire documentation period and the analyses up to cycle 6 in the company's dossier. This supports the evaluation in the dossier assessment that the analyses presented with the dossier were not adequate. Furthermore, for the outcomes mentioned above, the event time analyses up to cycle 6 showed several effect modifications by the characteristics of age, sex, and brain metastases at baseline, which are relevant to the dossier assessment. Due to the lack of analyses, it cannot be assessed whether there were effect modifications also in the analyses over the entire documentation period. The subsequently submitted event time analyses over the entire documentation period, and were therefore not used for the benefit assessment (results are presented as supplementary information in Appendix A). As had been the case in dossier assessment A20-87, the MMRM analyses were used for the benefit assessment instead (see Section 2.1.1).

Furthermore, the company submitted only analyses with the response criterion 10 points for the EQ-5D VAS. As explained in the General Methods of the Institute [6,7], for a response criterion to reflect with sufficient certainty a patient-noticeable change, however, it should correspond to at least 15% of the scale range of an instrument (in post-hoc analyses exactly 15% of the scale range). The analysis submitted subsequently by the company (response criterion 10 points) is therefore not suitable for the benefit assessment for this reason alone.

2.1.2 MMRM analyses on the instruments EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS

For the MMRM analyses for the patient-reported outcomes recorded using EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS used in the dossier assessment [1], the company subsequently submitted heterogeneity tests and subgroup analyses in its comments [3,4]. These were used for the benefit assessment.

Heterogeneity of the results between the cohorts (heterogeneity tests for the factor cohort)

Homogeneity of data between the global cohort and the cohort in China was shown for the outcomes mentioned above.

Subgroup analyses

The following subgroup characteristics were considered in the present benefit assessment:

- age (< $65/\geq 65$ years)
- sex (male/female)
- brain metastases at baseline (yes/no)

Based on the methods described in dossier assessment A20-87 [1], no relevant effect modifications were shown.

2.1.3 Event time analyses on the PGIC instrument

The data on time to deterioration (categories "much worse" and "very much worse") of the PGIC based on the meta-analysis, which were subsequently submitted by the company in its comments [3] are not suitable for the benefit assessment. It is unclear whether all available data were included in the event time analysis or whether only recordings up to cycle 6 were considered, as was the case in the company's dossier for the analyses of the instruments EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS. Kaplan-Meier curves, subgroup analyses, heterogeneity tests for the factor cohort, and analyses for the individual cohorts for this outcome were additionally missing. Therefore, the analyses of the PGIC were not used for the benefit assessment (results are presented as supplementary information in Appendix A).

2.2 Side effects

2.2.1 Analyses on AEs irrespective of the start of a subsequent therapy

In its comments, the company presented new analyses on AEs based on the meta-analysis. These included all events up to 90 days after the last dose of the study medication, but in contrast to the analyses in the company's dossier, irrespective of the start of a subsequent therapy. In principle, this is the preferable analysis for the benefit assessment, as it represents a longer observation period.

However, the analyses subsequently submitted by the company for the operationalization of AEs irrespective of the start of subsequent therapy were incomplete. Analyses are only available for the following superordinate AE outcomes:

- AEs
- serious AEs (SAEs)
- severe AEs (Common Terminology Criteria for Adverse Events [CTCAE] grade \geq 3)
- discontinuation due to AEs
- immune-related AEs, SAEs and severe AEs (CTCAE grade \geq 3)

Kaplan-Meier curves as well as subgroup analyses, heterogeneity tests for the factor cohort, analyses for the individual cohorts, analyses based on System Organ Classes (SOCs) and Preferred Terms (PTs) are not available for these analyses, however. Due to this, and because no relevant differences in the observed effects were shown in the overall rates compared with the analyses used for the dossier assessment, the analyses already available with the dossier were still used in the present situation. The subsequently submitted data on the AE outcomes are presented in Appendix A.

2.2.2 Immune-related severe AEs (CTCAE grade \geq 3) in women

The dossier showed an effect modification by the characteristic of sex for immune-related severe AEs (CTCAE grade \geq 3). However, the company did not provide a p-value for this outcome (e.g. an unstratified log-rank test would be possible) for the immune-related severe AEs in the subgroup of women in the dossier. The company did not provide a p-value for the immune-related severe AEs in women, neither in the comments nor (despite explicit request) subsequent to the oral hearing. In the final assessment, the effect modification is still taken into account and a possible hint of greater harm is not excluded.

2.3 Summary

The data subsequently submitted by the company in the commenting procedure have not changed the conclusion on the added benefit of durvalumab + chemotherapy from dossier assessment A20-87. The subsequently submitted subgroup analyses based on the MMRM analyses for the outcomes of EORTC QLQ-C30, QLQ-LC13 and EQ-5D VAS showed no relevant effect modifications and therefore had no impact on the benefit assessment.

As described in Chapter 2, the data submitted by the company are incomplete. Furthermore, the limitations of the CASPIAN study described in the dossier assessment have not been sufficiently dispelled after the commenting procedure, which is why the certainty of conclusions remains reduced. Therefore, at most hints, e.g. of an added benefit, can still be derived on the basis of the CASPIAN study.

The following Table 1 shows the result of the benefit assessment of durvalumab in combination with chemotherapy under consideration of dossier assessment A20-87 and the present addendum.

Addendum A21-19 Durvalumab – Addendum to Commission A20-87

Table 1: Durvalumab + chemotherapy ^a – probability and extent of added benefit						
Therapeutic indication	ACT ^b	Probability and extent of added benefit				

indication							
Extensive-stage small cell lung cancer (ES-SCLC) ^c	Cisplatin in combination with etoposide or carboplatin in combination with etoposide	 Men: hint of considerable added benefit Women: Hint of added benefit; extent "non- quantifiable", at most "considerable" 					
a. Cisplatin in combination with etoposide or carboplatin in combination with etoposide.b. Presentation of the respective ACT specified by the G-BA.							

c. The CASPIAN study only included patients with an ECOG PS of 0 or 1 and with asymptomatic or previously treated brain metastases. It remains unclear whether the observed effects can be transferred to patients with ECOG PS ≥ 2 or with symptomatic brain metastases.

ACT: appropriate comparator therapy; ECOG PS: Eastern Cooperative Oncology Group Performance Status; G-BA: Federal Joint Committee

The G-BA decides on the added benefit.

3 References

The reference list contains citations provided by the company in which bibliographical information may be missing.

1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Durvalumab (kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2020 [Accessed: 19.01.2021]. URL: <u>https://www.iqwig.de/download/A20-</u> <u>87_Durvalumab_Nutzenbewertung-35a-SGB-V_V1-0.pdf</u>.

2. AstraZeneca. Durvalumab (Imfinzi): Dossier zur Nutzenbewertung gemäß § 35a SGB V [online]. 2020 [Accessed: 19.01.2021]. URL: <u>https://www.g-</u> <u>ba.de/bewertungsverfahren/nutzenbewertung/596/#dossier</u>.

3. AstraZeneca. Stellungnahme zum IQWiG-Bericht Nr. 1015: Durvalumab (Neues Anwendungsgebiet: kleinzelliges Lungenkarzinom, Erstlinie, Kombination mit Etoposid und entweder Carboplatin oder Cisplatin); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung. [Demnächst verfügbar unter: <u>https://www.g-</u> <u>ba.de/bewertungsverfahren/nutzenbewertung/596/#beschluesse</u> im Dokument "Zusammenfassende Dokumentation"].

4. AstraZeneca. A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN); study D419QC00001; Zusatzanalysen eingereicht mit der Stellungnahme [unpublished]. 2021.

5. AstraZeneca. A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN); study D419QC00001; Nachreichung von Auswertungen nach der mündlichen Anhörung [unpublished]. 2021.

6. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dokumentation und Würdigung der Anhörung zum Entwurf der Allgemeinen Methoden 6.0 [online]. 2020 [Accessed: 27.01.2021]. URL: <u>https://www.iqwig.de/methoden/allgemeine-methoden_dwa-entwurf-fuer-version-6-0_v1-0.pdf</u>.

7. Institute for Quality and Efficiency in Health Care. General Methods; Version 6.0 [online]. 2020 [Accessed: 04.06.2021]. URL: <u>https://www.iqwig.de/methoden/general-methods_version-6-0.pdf</u>.

Appendix A – Event time analyses PGIC, EQ-5D VAS, EORTC QLQ-C30 + QLQ-LC13, AEs irrespective of the start of subsequent therapy

A.1 – Event time analyses PGIC and EQ-5D VAS

Table 2: Results (morbidity, time to event) – RCT, direct comparison: durvalumab + chemotherapy^a vs. chemotherapy^a

Outcome category Outcome Study	Durvalumab + chemotherapy ^a		Chemotherapy ^a		Durvalumab + chemotherapy ^a vs. chemotherapy ^a	
Study	N	Median time to event in months [95% CI] Patients with event n (%)	nonthsevent in monthsCI][95% CI]withPatients withatevent		HR [95% CI]; p-value ^b	
Morbidity						
Health status (EQ-5D VAS	S, time	to deterioration ^c)				
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	6.9 [4.6; 12.9] 147 (45.8)	321	9.2 [6.4; 12.3] 120 (37.4)	1.10 [0.86; 1.40]; 0.470	
Health status (PGIC, time	to deter	rioration ^d)				
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	NA	321	NA	0.54 [0.31; 0.93]; 0.023	
		26 (8.8)		28 (9.9)		

a. Cisplatin in combination with etoposide or carboplatin in combination with etoposide.

b. HR and 95% CI: stratified Cox proportional hazards model; p-value: stratified log-rank test; each stratified by the planned platinum-based chemotherapy at cycle 1 (cisplatin/carboplatin); for the meta-analysis additionally by cohort (Global/China).

c. Time to first deterioration, defined as decrease of the score by at least 10 points compared with baseline.

d. Patients from one study centre in Ukraine were not considered due to incorrect data recording. These were 16 (information in the CSR) or 17 (information in the SAP) randomized patients.

e. Calculated from meta-analysis.

f. A total of 2 patients were included in both the cohort in China and the global cohort. These patients were assigned to the cohort in China for the meta-analysis.

g. Time to first deterioration; deterioration defined as patients in categories "very much worse" and "much worse".

CI: confidence interval; CSR: Clinical Study Report; EQ-5D: European Quality of Life-5 Dimensions; HR: hazard ratio; N: number of analysed patients; n: number of patients with event; NA: not achieved; NC: not calculable; PGIC: Patient Global Impression of Change; RCT: randomized controlled trial; SAP: statistical analysis plan; VAS: visual analogue scale; vs.: versus

A.2 – Kaplan-Meier curves EQ-5D VAS




Figure 1: Kaplan-Meier curves on health status, EQ-5D VAS

A.3 – Event time analyses EORTC QLQ-C30 and QLQ-LC13

Table 3: Results (morbidity, health-related quality of life) – RCT, direct comparison:
durvalumab + chemotherapy ^a vs. chemotherapy ^a (multipage table)

Outcome category Outcome Study	Durvalumab + chemotherapy ^a		Chemotherapy ^a		Durvalumab + chemotherapy ^a vs. chemotherapy ^a	
	N	Median time to event in months [95% CI] Patients with event n (%)	N	Median time to event in months [95% CI] Patients with event n (%)	HR [95% CI]; p-value ^b	
Morbidity						
EORTC QLQ-C30 (syn	nptom	n scales, time to deter	rioration	l ^c)		
Fatigue						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	2.8 [2.1; 3.7] 186 (57.9)	321	2.2 [1.6; 3.0] 178 (55.5)	0.94 [0.76; 1.15]; 0.551	
Nausea and vomiting						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	-	
Total ^{d, e, f}	321	6.2 [3.0; 8.7] 159 (49.5)	321	4.6 [2.8; 7.2] 150 (46.7)	0.92 [0.74; 1.16]; 0.503	
Pain						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	5.6 [4.6; 7.2] 167 (52.0)	321	7.4 [5.8; 9.5] 127 (39.6)	1.17 [0.93; 1.48]; 0.181	
Dyspnoea						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	NA [8.5; NC] 119 (37.1)	321	10.2 [8.2; NC] 105 (32.7)	1.01 [0.77; 1.31]; 0.960	
Insomnia						
$CASPIAN-Global^d$	261	ND	260	ND	-	
CASPIAN – China	61	ND	62	ND	-	
Total ^{d, e, f}	321	11.7 [7.2; NC] 128 (39.9)	321	8.0 [6.5; NC] 120 (37.4)	0.90 [0.70; 1.16]; 0.433	
Appetite loss						
CASPIAN – Global ^d	261	ND	260	ND	-	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	6.8 [4.7; 12.0] 154 (48.0)	321	6.4 [4.4; 9.0] 140 (43.6)	0.93 [0.74; 1.17]; 0.552	

Addendum A21-19

Durvalumab - Addendum to Commission A20-87

Outcome category Outcome Study	Durvalumab + chemotherapy ^a		Chemotherapy ^a		Durvalumab + chemotherapy ^a vs. chemotherapy ^a	
	Ν	Median time to event in months [95% CI] Patients with event n (%)	Ν	Median time to event in months [95% CI] Patients with event n (%)	HR [95% CI]; p-value ^b	
Constipation						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	13.0 [7.6; 19.1] 132 (41.1)	321	NA [9.3; NC] 106 (33.0)	1.11 [0.86; 1.44]; 0.415	
Diarrhoea						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	31.1 [31.1; NC] 80 (24.9)	321	NA [11.2; NC] 86 (26.8)	0.75 [0.55; 1.03]; 0.073	
EORTC QLQ-LC13 (sy	ympto	m scales, time to det	terioratic	on ^c)		
Alopecia						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	0.8 [0.8; 0.8] 265 (82.6)	321	0.8 [0.8; 0.8] 256 (79.8)	1.02 [0.86; 1.22]; 0.809	
Haemoptysis						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	NA	321	NA	0.81 [0.51; 1.29]; 0.377	
		38 (11.8)		37 (11.5)		
Dysphagia						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	NA [17.6; NC] 90 (28.0)	321	25.9 [NC] 74 (23.1)	0.98 [0.72; 1.34]; 0.911	
Dyspnoea						
$CASPIAN-Global^d$	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	5.6 [3.7; 7.4] 164 (51.1)	321	3.8 [2.6; 6.4] 155 (48.3)	0.91 [0.73; 1.14]; 0.412	

Table 3: Results (morbidity, health-related quality of life) – RCT, direct comparison: durvalumab + chemotherapy^a vs. chemotherapy^a (multipage table)

Addendum A21-19

Durvalumab – Addendum to Commission A20-87

Outcome category Outcome Study	Durvalumab + chemotherapy ^a		Chemotherapy ^a		Durvalumab + chemotherapy ^a vs. chemotherapy ^a	
·	Ν	Median time to event in months [95% CI] Patients with event n (%)	Ν	Median time to event in months [95% CI] Patients with event n (%)	HR [95% CI]; p-value ^b	
Cough						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	NA [13.8; NC] 105 (32.7)	321	NA [10.2; NC] 93 (29.0)	0.96 [0.73; 1.28]; 0.788	
Sore mouth						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	22.8 [11.5; NC] 104 (32.4)	321	17.1 [17.1; 25.9] 85 (26.5)	1.02 [0.76; 1.36]; 0.902	
Peripheral neuropathy						
CASPIAN – Global ^d	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	7.9 [6.0; 12.9] 135 (42.1)	321	6.3 [4.8; 10.2] 122 (38.0)	0.87 [0.68; 1.12]; 0.275	
Pain (arm/shoulder)						
$CASPIAN - Global^d$	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	13.9 [9.5; NC] 120 (37.4)	321	8.7 [6.2; NC] 116 (36.1)	0.83 [0.64; 1.07]; 0.150	
Pain (chest)						
$CASPIAN - Global^d$	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	NA [12.9; NC] 109 (34.0)	321	NA [11.1; NC] 90 (28.0)	1.05 [0.8; 1.4]; 0.717	
Pain (other)						
$CASPIAN - Global^d$	261	ND	260	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{d, e, f}	321	6.5 [4.9; 12.0] 153 (47.7)	321	10.0 [5.6; 12.7] 122 (38.0)	1.06 [0.83; 1.34]; 0.661	

Table 3: Results (morbidity, health-related quality of life) – RCT, direct comparison: durvalumab + chemotherapy^a vs. chemotherapy^a (multipage table)

Addendum A21-19	Ve
Durvalumab – Addendum to Commission A20-87	12 Ma

Table 3: Results (morbidity, health-related quality of life) – RCT, direct comparison:
durvalumab + chemotherapy ^a vs. chemotherapy ^a (multipage table)

Outcome category Outcome Study	Durvalumab + chemotherapy ^a		C	^c hemotherapy ^a	Durvalumab + chemotherapy ^a vs. chemotherapy ^a
Study	N	Median time to event in months [95% CI] Patients with	N	Median time to event in months [95% CI] Patients with	HR [95% CI]; p-value ^b
		event n (%)		event n (%)	
Health-related quality	of lif	е			
EORTC QLQ-C30 (fun	ctiona	al scales) ^g			
Global health status					
$CASPIAN - Global^d$	261	ND	260	ND	
CASPIAN – China	61	ND	62	ND	
Total ^{d, e, f}	321	12.7 [7.9; NC] 127 (39.6)	321	8.4 [6.5; 14.1] 118 (36.8)	0.87 [0.67; 1.12]; 0.267
Physical functioning					
$CASPIAN - Global^d$	261	ND	260	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{d, e, f}	321	13.1 [7.9; NC] 126 (39.3)	321	6.3 [4.4; 9.5] 135 (42.1)	0.74 [0.58; 0.95]; 0.019
Role functioning					
$CASPIAN - Global^d$	261	ND	260	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{d, e, f}	321	5.6 [3.6; 7.7] 164 (51.1)	321	4.5 [3.1; 6.7] 149 [46.4]	0.97 [0.77; 1.21]; 0.801
Emotional functioning					
$CASPIAN-Global^{d}$	261	ND	260	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{d, e, f}	321	NA [12.9; NC] 102 (31.8)	321	17.8 [7.3; NC] 99 (30.8)	0.79 [0.60; 1.05]; 0.110
Cognitive functioning					
$CASPIAN-Global^d$	261	ND	260	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{d, e, f}	321	5.7 [4.6; 8.8] 157 (48.9)	321	5.6 [4.6; 6.5] 142 (44.2)	0.88 [0.70; 1.11]; 0.298
Social functioning					
$CASPIAN-Global^d$	261	ND	260	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{d, e, f}	321	5.6 [2.8; 6.9] 170 (53.0)	321	4.4 [3.0; 7.2] 153 (47.7)	0.93 [0.75; 1.17]; 0.545

Addendum A21-19	Version 1.0
Durvalumab – Addendum to Commission A20-87	12 March 2021

Outcome category Outcome Study		Durvalumab + chemotherapy ^a		Chemotherapy ^a	Durvalumab + chemotherapy ^a vs. chemotherapy ^a	
	N	Median time to event in months [95% CI]	N	Median time to event in months [95% CI]	HR [95% CI]; p-value ^b	
		Patients with event		Patients with event		
		n (%)		n (%)		

Table 3: Results (morbidity, health-related quality of life) – RCT, direct comparison: durvalumab + chemotherapy^a vs. chemotherapy^a (multipage table)

a. Etoposide + carboplatin or etoposide + cisplatin.

b. HR and 95% CI: stratified Cox proportional hazards model; p-value: stratified log-rank test; each stratified by the planned platinum-based chemotherapy at cycle 1 (cisplatin/carboplatin); for the meta-analysis additionally by cohort (Global/China).

c. Time to first deterioration, defined as increase of the score by at least 10 points compared with baseline.

d. Patients from one study centre in Ukraine were not considered due to incorrect data recording. These were 16 (information in the CSR) or 17 (information in the SAP) randomized patients.

e. Calculated from meta-analysis.

f. A total of 2 patients were included in both the cohort in China and the global cohort. These patients were assigned to the cohort in China for the meta-analysis.

g. Time to first deterioration, defined as decrease of the score by at least 10 points compared with baseline.

CI: confidence interval; CSR: Clinical Study Report; EORTC: European Organisation for Research and Treatment of Cancer; HR: hazard ratio; N: number of analysed patients; n: number of patients with event; NA: not achieved; NC: not calculable; ND: no data; QLQ-C30: Quality of Life Questionnaire-Core 30; QLQ-LC13: Quality of Life Questionnaire-Lung Cancer 13; RCT: randomized controlled trial; SAP: statistical analysis plan; vs.: versus

A.4 – Kaplan-Meier curves on EORTC QLQ-C30 and QLQ-LC13 symptom scales




Figure 2: Kaplan-Meier curves on symptoms, symptom scale "fatigue" (EORTC QLQ-C30)




Figure 3: Kaplan-Meier curves on symptoms, symptom scale "nausea and vomiting" (EORTC QLQ-C30)




Figure 4: Kaplan-Meier curves on symptoms, symptom scale "pain" (EORTC QLQ-C30)




Figure 5: Kaplan-Meier curves on symptoms, symptom scale "dyspnoea" (EORTC QLQ-C30)

IEMT0184 - CASPIAN (D419QC00001) DCO: Global (27JAN2020) China (06Jan2020) Page 1 of 1 Figure fqc30_1.4.2_all_META Kaplan-Meier plot for time to deterioration (months) - EORTC QLQ-C30 subscales / items (MID 10) (Full analysis set, Combined Global and China Cohorts) QLC-QC30 Sleep 1.0




Figure 6: Kaplan-Meier curves on symptoms, symptom scale "insomnia" (EORTC QLQ-C30)




Figure 7: Kaplan-Meier curves on symptoms, symptom scale "appetite loss" (EORTC QLQ-C30)

Durvalumab - Addendum to Commission A20-87




Figure 8: Kaplan-Meier curves on symptoms, symptom scale "constipation" (EORTC QLQ-C30)




Figure 9: Kaplan-Meier curves on symptoms, symptom scale "diarrhoea" (EORTC QLQ-C30)




Figure 10: Kaplan-Meier curves on symptoms, symptom scale "alopecia" (EORTC QLQ-LC13)




Figure 11: Kaplan-Meier curves on symptoms, symptom scale "haemoptysis" (EORTC QLQ-LC13)




Figure 12: Kaplan-Meier curves on symptoms, symptom scale "dysphagia" (EORTC QLQ-LC13)




Figure 13: Kaplan-Meier curves on symptoms, symptom scale "dyspnoea" (EORTC QLQ-LC13)




Figure 14: Kaplan-Meier curves on symptoms, symptom scale "cough" (EORTC QLQ-LC13)




Figure 15: Kaplan-Meier curves on symptoms, symptom scale "sore mouth" (EORTC QLQ-LC13)




Figure 16: Kaplan-Meier curves on symptoms, symptom scale "peripheral neuropathy" (EORTC QLQ-LC13)




Figure 17: Kaplan-Meier curves on symptoms, symptom scale "pain (arm/shoulder)" (EORTC QLQ-LC13)




Figure 18: Kaplan-Meier curves on symptoms, symptom scale "pain (chest)" (EORTC QLQ-LC13)




Figure 19: Kaplan-Meier curves on symptoms, symptom scale "pain (other)" (EORTC QLQ-LC13)

A.5 – Kaplan-Meier curves on global health status and EORTC QLQ-C30 functional scales




Figure 20: Kaplan-Meier curves on health-related quality of life, scale "global health status" (EORTC QLQ-C30)




Figure 21: Kaplan-Meier curves on health-related quality of life, scale "physical functioning" (EORTC QLQ-C30)




Figure 22: Kaplan-Meier curves on health-related quality of life, scale "role functioning" (EORTC QLQ-C30)




Figure 23: Kaplan-Meier curves on health-related quality of life, scale "emotional functioning" (EORTC QLQ-C30)

Durvalumab - Addendum to Commission A20-87




Figure 24: Kaplan-Meier curves on health-related quality of life, scale "cognitive functioning" (EORTC QLQ-C30)




Figure 25: Kaplan-Meier curves on health-related quality of life, scale "social functioning" (EORTC QLQ-C30)

A.6 – AEs irrespective of the start of a subsequent therapy

Table 4: Results (side effects) – RCT, direct comparison: durvalumab + chemotherapy ^a vs.
chemotherapy ^a (multipage table)

Outcome category Outcome Study	Durvalumab + chemotherapy ^a		Chemotherapy ^a		Durvalumab + chemotherapy ^a vs. chemotherapy ^a
Study	N	Median time to event in months [95% CI] Patients with event n (%)	N	Median time to event in months [95% CI] Patients with event n (%)	HR [95% CI]; p-value ^b
Side effects		(17)			
AEs (supplementary inf	ormatio	on; until 90 days afte	r the las	t dose of the study m	edication)
CASPIAN – Global	265	ND	266	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{c, d}	325	0.3 [0.2; 0.3] 320 (98.5)	327	0.3 [0.2; 0.3] 318 (97.2)	_
SAEs (until 90 days afte	er the la	ast dose of the study	medicat	ion)	
CASPIAN – Global	265	ND	266	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{c, d}	325	NA [22.9; NC] 110 (33.8)	327	NA 119 (36.4)	0.78 [0.60; 1.02]; 0.072
Severe AEs ^e (until 90 d	avs afte	, ,	study n	· · ·	
CASPIAN – Global	265	ND	266	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{c, d}	325	0.5 [0.3; 0.7] 219 (67.4)	327	0.5 [0.3; 0.7] 222 (67.9)	0.98 [0.82; 1.18]; 0.855
Discontinuation due to	AEs ^f (u	. ,	last dos	· · · ·	ation)
CASPIAN – Global	265	ND	266	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{c, d}	325	NA 37 (11.4)	327	NA 32 (9.8)	0.99 [0.61; 1.62]; 0.974
mmune-related AEs (su	upplem	entary information; u	until 90	days after the last dos	se of the study medication)
CASPIAN – Global	265	ND	266	ND	
CASPIAN – China	61	ND	62	ND	_
Total ^{c, d}	325	21.6 [11.2; NC] 123 (37.8)	327	NA 71 (21.7)	-
mmune-related SAEs (until 90) days after the last d	ose of t	he study medication)	
CASPIAN – Global	265	ND	266	ND	_
CASPIAN – China	61	ND	62	ND	_
Total ^{c, d}					Heterogeneity unclear ^g

Durvalumab - Addendum to Commission A20-87

Table 4: Results (side effects) – RCT, direct comparison: durvalumab + chemotherapy ^a vs.
chemotherapy ^a (multipage table)

Outcome category Outcome Study	-	Durvalumab + chemotherapy ^a		'hemotherapy ^a	Durvalumab + chemotherapy ^a vs. chemotherapy ^a	
	N	Median time to event in months [95% CI] Patients with event n (%)	N	Median time to event in months [95% CI] Patients with event n (%)	HR [95% CI]; p-value ^b	
Immune-related severe AEs ^e (until 90 days after the last dose of the study medication)						
CASPIAN – Global	265	ND	266	ND	_	
CASPIAN – China	61	ND	62	ND	_	
Total ^{c, d}	325	14 (4.3)	327	6 (1.8)	1.91 [0.73; 5.50]; 0.188	

a. Cisplatin in combination with etoposide or carboplatin in combination with etoposide.

b. HR [95% CI] from unstratified Cox regression model, p-value based on likelihood ratio test.

c. Calculated from meta-analysis.

d. A total of 2 patients were included in both the cohort in China and the global cohort. These patients were assigned to the cohort in China for the meta-analysis.

e. Operationalized as CTCAE grade ≥ 3 .

f. Discontinuation of at least one drug component.

g. For the analysis used in the dossier assessment, there is a statistically significant heterogeneity for the factor cohort for the outcome "immune-related SAEs". As the company did not provide any heterogeneity tests for the factor cohort for the subsequently submitted analyses on AEs up to 90 days after the last dose of the study medication, irrespective of the start of a subsequent therapy, statistically significant heterogeneity cannot be excluded. The data are therefore not presented.

AE: adverse event; CI: confidence interval; CTCAE: Common Terminology Criteria for Adverse Events; HR: hazard ratio; N: number of analysed patients; n: number of patients with (at least one) event; NA: not achieved; NC: not calculable; ND: no data; RCT: randomized controlled trial; SAE: serious adverse event; vs.: versus